CAJ | 학술논문

目的：观察艾迪注射液联合顺铂与氟尿嘧啶治疗晚期食管癌的临床疗效。方法将46例晚期食管癌患者随机分为观察组（24例）和对照组（22例），观察组给予顺铂30mg·m-2，静脉注射，第1～3天，氟尿嘧啶500mg·m-2，静脉注射，第1～5天，28天为1个周期，连用2个周期，化疗同时给予艾迪注射液，50mL 加入5％葡萄糖注射液500mL静脉滴注，每日1次，连用14天。对照组单纯化疗，方案同观察组。结果观察组和对照组近期疗效有效率分别为41.6％和40.9％，无显著性差异（P>0.05）。观察组临床症状改善率和 KPS 评分提高率显著高于对照组（P<0.05），观察组 II 度以上白细胞和血小板减少的发生率显著低于对照组（P<0.05）。结论艾迪注射液可以改善晚期食管癌患者的临床症状，减轻化疗不良反应，提高患者的生活质量，艾迪注射液联合 PF 方案化疗能取得更好的临床收益。
목적：관찰애적주사액연합순박여불뇨밀정치료만기식관암적림상료효。방법장46례만기식관암환자수궤분위관찰조（24례）화대조조（22례），관찰조급여순박30mg·m-2，정맥주사，제1～3천，불뇨밀정500mg·m-2，정맥주사，제1～5천，28천위1개주기，련용2개주기，화료동시급여애적주사액，50mL 가입5％포도당주사액500mL정맥적주，매일1차，련용14천。대조조단순화료，방안동관찰조。결과관찰조화대조조근기료효유효솔분별위41.6％화40.9％，무현저성차이（P>0.05）。관찰조림상증상개선솔화 KPS 평분제고솔현저고우대조조（P<0.05），관찰조 II 도이상백세포화혈소판감소적발생솔현저저우대조조（P<0.05）。결론애적주사액가이개선만기식관암환자적림상증상，감경화료불량반응，제고환자적생활질량，애적주사액연합 PF 방안화료능취득경호적림상수익。
Objective To observe the therapeutic efficacy of Aidi injection combined with cisplation and 5-fluorouracil (PF regimen) chemotherapy in treatment of advanced esophageal cancer. Methods 46 cases of advanced esophageal cancer~were di-vided randomly into two groups. 24 patients of observation group were treated with Aidi injection (50 mL, d1~d14) combined with cisplation (DDP 30 mg·m-2, d1~d3) and 5-fluorouracil (5-Fu 500 mg·m-2, d1~d5). A cycle last 28 days and they had continu-ous two cycles. 22 patients of control group only received PF Chemotherapy as observation group. The therapeutic efficacy of the two groups was evaluated after two cycles of treatment. Results The overall response rates of observation group and control group were respectively 41.6% and 40.9%, and there was no statistically significant difference (P>0.05). The symptoms control rate of observation group was higher than that of control group (P<0.05). The life quality of patients in observation group was superior to the patients in control group (P<0.05). II~IV degree myelosuppression rate of observation group was lower than that of control group (P<0.05). Conclusion Aidi injection has the function of alleviating the symptoms and poisonous side-effect of chemotherapy medicine and improving life quality of patients with advanced esophageal cancer.